.jpg)
Neuroendocrine Cancer UK - Not Just NE Cancer Podcast
Real life experiences, practical advice and everything in between. Whether you are diagnosed with Neuroendocrine Cancer or another rare or less common cancer, our podcast series cover topics from initial diagnosis, treatments and follow up, looking after your mental health and the professional perspectives from those involved in your care. Hosted by Catherine Bouvier and produced by Neuroendocrine Cancer UK. We hope this series answers some of your questions or provides a source of support - or both, after all, this is not just NE cancer.
Neuroendocrine Cancer UK - Not Just NE Cancer Podcast
Neuroendocrine Cancer UK Explores RareCan's Innovative Research Platform
Welcome to the latest episode of the "Not Just NE Cancer Takeover Series." Following our successful launch last week, this series continues to delve into the world of neuroendocrine cancer research, with a specific focus on our newly introduced 'Advancing Neuroendocrine Cancer Research' campaign.
In this second episode, Campaigns Lead Lisa engages in a compelling discussion with Andy Hall, Co-founder & Chief Scientific Officer of RareCan. RareCan, a digital health company, has created an inclusive community of members who willingly share valuable information about their cancer experiences. By building cohorts, this platform empowers patients and enables researchers to locate them with a simple keystroke. Additionally, RareCan, established in 2020, provides a suite of member-designed tools that assist individuals in managing their lives while living with rare cancers.
The significance of RareCan lies in its ability to streamline the research process by facilitating the identification of individuals diagnosed with neuroendocrine cancer each year. This episode delves into the unique challenges faced within the realm of rare cancer research and sheds light on the innovative approaches undertaken by the RareCan research platform. Join Lisa and Andy as they discuss these challenges and explore the ways in which RareCan is striving to overcome them, all while offering individuals within the neuroendocrine cancer community the opportunity to actively participate in research.
Further information:
